Abstract

Background HIV-1 RNA is a key parameter for reliable diagnosis and treatment of HIV-1 infection. The determination of HIV-1 RNA reduces the pre-seroconversion period in the diagnosis of HIV-1 infection and supports clinical management of HIV-1-infected patients. Objectives and study design The COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test combines automated extraction of total nucleic acids on the COBAS ® AmpliPrep Instrument with real-time PCR on the COBAS ® TaqMan ® Analyzer, thus greatly reducing hands-on time during sample preparation and amplification/detection. The test was evaluated for sensitivity, dynamic range, precision, subtype inclusivity, interfering substances, diagnostic and analytical specificity, as well as correlation with three other commercial tests for HIV-1 RNA quantification. Results The COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test demonstrated an assay sensitivity of 40 copies/mL, a greater than 5 log 10 measuring range of 40–1.0E+07 copies/mL (1.6–7.0 log 10) and a reliable determination of HIV-1 group M and N subtypes in EDTA plasma. Quantification results were highly correlated with those obtained by the COBAS ® AMPLICOR ® HIV-1 MONITOR Test v1.5, the COBAS ® AmpliPrep/COBAS ® AMPLICOR ® HIV-1 MONITOR Test v1.5 and the VERSANT ® HIV-1 RNA 3.0 assay. Conclusions The COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test excellently satisfies the requirements for reliable quantification of HIV-1 RNA in clinical specimens by a broad linear measuring range and a fully automated quantification procedure. It is highly appropriate for therapy monitoring and routine management of HIV-1 infection.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.